摘要
采用葡萄球菌凝固酶激活法,测定了41例原发性肝癌(HCC)和其他疾病的血浆r-去羧凝血酶原(DCP)含量。结果健康成人的DCP含量均小于60mu/ml,用于诊断HCC的阳性率为70.7％..显著高于其他疾病(P<0.01)。其中17例小肝癌之阳性检出率为76.4％,若联合检测DCP与αFP则可将阳性率提高到80.4％。4例经肝叶切除的HCC,于术后二周DCP值恢复正常。似可以说明DCP与肝癌细胞本身有关。本文提示,这种新的测定DCP的方法具有灵敏,特异,简便,快速等特点,可能是诊断HCC最有希望的标志物。
A new method for assaying the activity of DCP in 41 patients with hepatocellular carcinoma (HCC), other malignancies and healthy subjects, using staphylocoagulase, was reported. levels of DCP in healthy subjects were under 60mU/ml. Of 41 HOC patients, 70.7% had elevated DCP values, It showed a significant high value (P<0.01) as compared with that in other malignanancies and healthy subjects.The diagnostic positive rate in 17 cases of small HCC was 76.4%. Combined measurement of DCP and α-FP gave a complementary information, the positive rate increased to 80.4%. DCP levels reduced to the normal limit were found in 4 patients two weeks after hepatectomies. This result indicates that DCP is probably synthesized by hepatoma cells. In conclusion, DCP may be a sensitive, specific and useful tumor marker in the diagnosis of HCC, especially in small HCC.
出处
《军医进修学院学报》
CAS
1990年第2期95-97,共3页
Academic Journal of Pla Postgraduate Medical School
